Meeting
2022 ASCO Genitourinary Cancers Symposium
A phase II study of talazoparib and avelumab in VHL deficient clear cell renal cell carcinoma.
Authors
Ritesh Kotecha
Memorial Sloan Kettering Cancer Center, New York, NY
Ritesh Kotecha , Chung-Han Lee , Deaglan Joseph McHugh , Chloe Dadoun , Andrea Knezevic , Maria Isabel Carlo , Emily Feld , Natalie Shapnik , Neil J. Shah , Darren R. Feldman , Robert J. Motzer , Martin H Voss
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Renal Cell Cancer; Adrenal, Penile, Urethral, and Testicular Cancers
Track
Renal Cell Cancer,Adrenal Cancer,Penile Cancer,Testicular Cancer,Urethral Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04068831
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 347)
DOI
10.1200/JCO.2022.40.6_suppl.347
Abstract #
347
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Annual Meeting
A phase II study of talazoparib plus avelumab in patients with stage IV or recurrent nonsquamous non–small cell lung cancer bearing pathogenic STK11 genomic alterations (SWOG S1900C, LUNG-MAP sub-study, NCT04173507).
First Author: Ferdinandos Skoulidis
Poster
2019 ASCO Annual Meeting
JAVELIN BRCA/ATM: A phase 2 trial of avelumab (anti–PD-L1) plus talazoparib (PARP inhibitor) in patients with advanced solid tumors with a BRCA1/2 or ATM defect.
First Author: David Michael Hyman
Poster
2021 ASCO Annual Meeting
A phase II clinical trial of talazoparib monotherapy for PALB2 mutation‑associated advanced breast cancer.
First Author: Joshua James Gruber
Poster
2020 ASCO Virtual Scientific Program
Clinically advanced renal cell carcinoma (RCC) and renal sarcoma (RSC) in young patients: A comprehensive genomic profiling (CGP) study.
First Author: Gennady Bratslavsky